- Home
- CNC vs RPRX Comparison
CNC vs RPRX Comparison
Compare CNC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNC
- RPRX
- Stock Information
- Founded
- CNC 1984
- RPRX 1996
- Country
- CNC United States
- RPRX United States
- Employees
- CNC N/A
- RPRX N/A
- Industry
- CNC Medical Specialities
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNC Health Care
- RPRX Health Care
- Exchange
- CNC Nasdaq
- RPRX Nasdaq
- Market Cap
- CNC 14.3B
- RPRX 15.6B
- IPO Year
- CNC 2001
- RPRX 2020
- Fundamental
- Price
- CNC $32.29
- RPRX $35.64
- Analyst Decision
- CNC Hold
- RPRX Strong Buy
- Analyst Count
- CNC 16
- RPRX 3
- Target Price
- CNC $38.33
- RPRX $45.33
- AVG Volume (30 Days)
- CNC 13.8M
- RPRX 4.1M
- Earning Date
- CNC 10-24-2025
- RPRX 11-05-2025
- Dividend Yield
- CNC N/A
- RPRX 2.47%
- EPS Growth
- CNC N/A
- RPRX 54.86
- EPS
- CNC 4.07
- RPRX 2.32
- Revenue
- CNC $159,673,000,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- CNC $30.26
- RPRX $35.01
- Revenue Next Year
- CNC N/A
- RPRX $3.14
- P/E Ratio
- CNC $7.87
- RPRX $15.33
- Revenue Growth
- CNC 10.73
- RPRX 3.02
- 52 Week Low
- CNC $25.08
- RPRX $24.05
- 52 Week High
- CNC $77.29
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- CNC 58.34
- RPRX 45.47
- Support Level
- CNC $31.73
- RPRX $34.84
- Resistance Level
- CNC $36.14
- RPRX $35.84
- Average True Range (ATR)
- CNC 1.22
- RPRX 0.84
- MACD
- CNC 0.38
- RPRX -0.08
- Stochastic Oscillator
- CNC 51.20
- RPRX 48.64
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.